Claims
- 1. A compound of formula (I): ##STR30## wherein: Y.sup.1 is sulphur, --SO--, or --SO.sub.2 --;
- R.sup.1 is hydrogen or an amino protecting group;
- R.sup.2 is (C.sub.1-12)alkyl, (C.sub.2-12)alkenyl, (C.sub.2-12)alkynyl, (C.sub.3-7)cycloalkyl, (C.sub.5-8)cycloalkenyl, each of which is substituted by a phenyl group which may be unsubstituted or substituted up to 3 times with (C.sub.1-6)alkoxy or hydroxy or a (C.sub.1-6)alkylene dioxy group; and wherein each of the R.sup.2 substituents hereinbefore defined, is also substituted by carboxyl or esterified carboxy; and
- CO.sub.2 R.sup.3 is carboxy or a carboxylate anion, or the group R.sup.3 is a readily removable carboxy protecting group;
- Y.sup.2 is a group of the formula: ##STR31## wherein the pyridinium group is unsubstituted or substituted at a ring carbon atom available for substitution by up to four substituents selected from (C.sub.1-6)alkyl, and (C.sub.1-6)alkoxy;
- R.sup.4 and R.sup.5 which may be the same or different are selected from hydrogen, a group R.sup.6, or a readily removable amino protecting group;
- R.sup.6 is (C.sub.1-6)alkyl, (C.sub.3-7)cycloalkyl, (C.sub.2-6)alkenyl, (C.sub.5-8)cycloalkenyl, (C.sub.2-6)alkynyl, each of which may be unsubstituted or substituted by halogen, cyano, azido, nitro, carboxy, (C.sub.1-6)alkoxycarbonyl, carbamoyl, mono- or di-(C.sub.1-6)alkylcarbamoyl, sulphono, sulphamoyl, mono- and di-(C.sub.1-6)alkylsulphamoyl, amino, mono- and di-(C.sub.1-6)alkylamino, acylamino, (C.sub.1-6)alkoxycarbonylamino, hydroxy, (C.sub.1-6)alkoxy, acyloxy, oxo, phenylcarbonyl, naphthylcarbonyl, heterocyclylcarbonyl, (C.sub.1-6)alkylthio, (C.sub.1-6)alkanesulphinyl, (C.sub.1-6)alkanesulphonyl, phenyl, naphthyl or heterocyclyl; wherein the phenyl or naphthyl may be unsubstituted or substituted up to 5 times by halogen, (C.sub.1-6)alkyl, phenyl, (C.sub.1-6)alkoxy, hydroxy(C.sub.1-6)alkyl, mercapto(C.sub.1-6)alkyl, halo(C.sub.1-6)alkyl, mercapto, hydroxy, amino, mono- or di-(C.sub.1-6)alkylamino, nitro, carboxy, (C.sub.1-6)alkoxycarbonyl, (C.sub.1-6)alkoxycarbonyl(C.sub.1-6)alkyl, (C.sub.1-6)alkylcarbonyloxy, formyl, or (C.sub.1-6)alkylcarbonyl; wherein the heterocyclyl moiety may be unsubstituted or substituted up to 3 times by (C.sub.1-6)alkyl, (C.sub.1-6)alkoxy, (C.sub.1-6)alkoxy-(C.sub.1 -6)alkyl, halo(C.sub.1-6)alkyl, hydroxy, amino, mono- or di-(C.sub.1-6)alkylamino, acylamino, carboxy, carboxy salts, carboxy esters, carbamoyl, (C.sub.1-6)alkoxycarbonyl, phenyloxycarbonyl, naphthyloxycarbonyl, (C.sub.1-6)alkoxycarbonyl(C.sub.1-6)alkyl, oxo, or a phenyl or naphthyl group which is unsubstituted or substituted up to 5 times by halogen, (C.sub.1-6)alkyl, phenyl, (C.sub.1-6)alkoxy, hydroxy(C.sub.1-6)alkyl, mercapto(C.sub.1-6)alkyl, halo(C.sub.1-6)alkyl, mercapto, hydroxy, amino, mono- or di-(C.sub.1-6)alkylamino, nitro, carboxy, (C.sub.1-6)alkoxycarbonyl, (C.sub.1-6)alkoxycarbonyl(C.sub.1-6)alkyl, (C.sub.1-6)alkylcarbonyloxy, formyl, or (C.sub.1-6)alkylcarbonyl; and the heterocyclyl moiety is aromatic or non-aromatic, single or fused rings containing up to four heteroatoms in each ring selected from oxygen, nitrogen and sulphur;
- Y.sup.3 is nitrogen or --CH;
- X is an inorganic or organic anion; and
- n is 0 or 1; with the proviso that when (i) CO.sub.2 R.sup.3 is carboxylate n is O and (ii) CO.sub.2 R.sup.3 is carboxy or the group R.sup.3 is a readily removable carboxy protecting group, then n is 1 and the anion X is present in the appropriate stoichiometric proportion to balance the positive charge on the pyridinium group.
- 2. The compound according to claim 1 in which R.sup.2 is a substituted (C.sub.1-6)alkyl.
- 3. The compound according to claim 2 in which R.sup.2 is methyl substituted by a phenyl group which is unsubstituted or substituted up to 3 times by (C.sub.1-6)alkoxy or hydroxy.
- 4. The compound according to claim 3 in which the methyl is further substituted by a carboxy group.
- 5. The compound according to claim 2 in which R.sup.2 is carboxy(3,4-dihydroxyphenyl)methyl or (methylenedioxy)benzyl.
- 6. The compound according to claim 3 in which R.sup.4 and R.sup.5 are each selected from hydrogen, methyl, ethyl, carboxymethyl, methoxyethyl, cyanomethyl, propargyl, 4-carboxy-butan-1-yl, 2-amino-2-(methoxycarbonyl)ethyl, cyclopropylmethyl, propyl, cyclopentyl, prop-2-en-1-yl, butyl, hexyl, isopropyl, 2-hydroxyethyl, isoxazolylmethyl, thiazolylmethyl.
- 7. The compound according to claim 1 in which, in the group Y.sup.2, the pyridinium ring is bonded to sulphur by a ring carbon atom which is .alpha.- or .gamma.- to the pyridinium nitrogen.
- 8. A compound of formula (Ia) or a pharmaceutically acceptable salt or a pharmaceutically acceptable in vivo hydrolysable ester thereof: ##STR32## wherein R.sup.2, Y.sup.1, Y.sup.2, Y.sup.3 and n are as defined in claim 1, with the proviso that R.sup.4 and R.sup.5 is not a readily removable amino protecting group; the group CO.sub.2 R is carboxy or a carboxylate anion and Z is a pharmaceutically acceptable inorganic or organic anion present in the appropriate stoichiometric proportion to balance the positive charge on the pyridinium ring of the group Y.sup.2.
- 9. A compound of formula (I): ##STR33## wherein: Y.sup.1 is sulphur, --SO--, or --SO.sub.2 ;
- R.sup.1 is hydrogen or an amino protecting group;
- R.sup.2 is hydrogen, (C.sub.1-12)alkyl, (C.sub.2-12)alkenyl, (C.sub.2-12)alkynyl, (C.sub.3-7)cycloalkyl, (C.sub.5-8)cycloalkenyl, each of which may be unsubstituted or substituted by carboxyl, esterified carboxy, hydroxy, alkoxy, cyano, carbamoyl, N-substituted carbamoyl, phenyloxy, naphthyloxy, phenylalkoxy, naphthlalkoxy, mercapto, alkylthio, phenylthio, naphthylthio, amino, substituted amino, halogen, nitro, azido, formyl, acyl, acyloxy, pthalimido, acylamino, alkoxycarbonylamino, phenalkoxy-carbonylamino or naphthalkoxy-carbonylamino;
- CO.sub.2 R.sup.3 is carboxy or a carboxylate anion, or the group R.sup.3 is a readily removable carboxy protecting group;
- Y.sup.2 is a group of the formula: ##STR34## wherein the pyridinium group is unsubstituted or substituted by up to four substituents selected from (C.sub.1-6)alkyl and (C.sub.1-6)alkoxy;
- R.sup.4 and R.sup.5 which may be the same or different are selected from hydrogen, a group R.sup.6, or a readily removable amino protecting group; or
- R.sup.6 is (C.sub.1-6)alkyl, (C.sub.3-7)cycloalkyl, (C.sub.2-6)alkenyl, (C.sub.5-8)cycloalkenyl, (C.sub.2-6)alkynyl, each of which may be unsubstituted or substituted by halogen, cyano, azido, nitro, carboxy, (C.sub.1-6)alkoxycarbonyl, carbamoyl, mono- or di-(C.sub.1-6)alkylcarbamoyl, sulphono, sulphamoyl, mono- and di-(C.sub.1-6)alkylsulphamoyl, amino, mono- and di-(C.sub.1-6)alkylamino, acylamino, (C.sub.1-6)alkoxycarbonylamino, hydroxy, (C.sub.1-6)alkoxy, acyloxy, oxo, phenylcarbonyl, naphthylcarbonyl, heterocylcylcarbonyl, (C.sub.1-6)alkylthio, (C.sub.1-6)alkanesulphinyl, (C.sub.1-6)alkanesulphonyl, phenyl, naphthyl, or heterocyclyl; wherein the phenyl or naphthyl group may be unsubstituted or substituted up to 5 times by halogen, (C.sub.1-6)alkyl, phenyl, (C.sub.1-6)alkoxy, hydroxy(C.sub.1-6)alkyl, mercapto(C.sub.1-6)alkyl, halo(C.sub.1-6)alkyl, mercapto, hydroxy, amino, mono- or di-(C.sub.1-6)alkylamino, nitro, carboxy, (C.sub.1-6)alkoxycarbonyl, (C.sub.1-6)alkoxycarbonyl(C.sub.1-6)alkyl, (C.sub.1-6)alkylcarbonyloxy, formyl, or (C.sub.1-6)alkylcarbonyl; wherein the heterocyclyl moiety may be unsubstituted or substituted up to 3 times by (C.sub.1-6)alkyl, (C.sub.1-6)alkoxy, (C.sub.1-6)alkoxy(C.sub.1-6)alkyl, halo(C.sub.1-6)alkyl, hydroxy, amino, mono- or di-(C.sub.1-6)alkylamino, acylamino, carboxy, carboxy salts, carboxy esters, carbamoyl, (C.sub.1-6)alkoxycarbonyl, phenyloxycarbonyl, naphthyloxycarbonyl, (C.sub.1-6)alkoxycarbonyl(C.sub.1-6)alkyl, oxo, or a phenyl or naphthyl group which is unsubstituted or substituted up to 5 times by halogen, (C.sub.1-6)alkyl, phenyl, (C.sub.1-6)alkoxy, hydroxy(C.sub.1-6)-alkyl, mercapto(C.sub.1-6)alkyl, halo(C.sub.1-6)alkyl, mercapto, hydroxy, amino, mono- or di-(C.sub.1-6)alkylamino, nitro, carboxy, (C.sub.1-6)alkoxycarbonyl; (C.sub.1-6)alkoxycarbonyl(C.sub.1-6)alkyl, (C.sub.1-6)alkylcarbonyloxy, formyl, or (C.sub.1-6)alkylcarbonyl; and wherein the heterocyclyl moiety is aromatic or non-aromatic, single or fused rings containing up to four heteroatoms in each ring selected from oxygen, nitrogen and sulphur; or
- Y.sup.3 is nitrogen or CH;
- X is an inorganic or organic anion; and
- n is 0 or 1; with the proviso that when (i) CO.sub.2 R.sup.3 is carboxylate, n is 0, and (ii) CO.sub.2 R.sup.3 is carboxy or the group R.sup.3 is a readily removable carboxy protecting group, then n is 1 and the anion X is present in the appropriate stoichiometric proportion to balance the positive charge on the pyridinium group.
- 10. A compound of formula (II): ##STR35## wherein R.sup.1, R.sup.2, R.sup.3, X, Y.sup.1, Y.sup.2, Y.sup.3 and n are as defined with respect to formula (I) according to claim 1.
- 11. A compound of the formula (II): ##STR36## wherein R.sup.1, R.sup.2, R.sup.3, X, Y, Y.sup.2, Y.sup.3 and n are as defined with respect to formula (I) according to claim 9.
- 12. A pharmaceutical composition comprising a compound of formula (Ia) as defined in claim 8 or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, in combination with a pharmaceutically acceptable excipient or diluent.
- 13. The pharmaceutical composition as claimed in claim 12 further comprising a .beta.-lactamase inhibitor.
- 14. A method of treating bacterial infections in humans and animals which method comprises administering a therapeutically effective amount of a compound of formula (Ia) as defined in claim 8 or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof to a patient in need thereof.
- 15. A compound of formula (Ia) or a pharmaceutically acceptable salt or a pharmaceutically acceptable in vivo hydrolysable ester thereof: ##STR37## wherein R.sup.2, Y.sup.1, Y.sup.2, Y.sup.3 and n are as defined in claim 9, with the proviso that R.sup.4 and R.sup.5 is not a readily removable amino protecting group; the group CO.sub.2 R is carboxy or a carboxylate anion and Z is a pharmaceutically acceptable inorganic or organic anion present in the appropriate stoichiometric proportion to balance the positive charge on the pyridinium ring of the group Y.sup.2.
- 16. The compound according to claim 9 in which R.sup.2 is a substituted or unsubstitued (C.sub.1-6)alkyl, substituted or unsubstitued (C.sub.3-7)alkyl, or hydrogen.
- 17. The compound according to claim 16 wherein R.sup.2 is methyl substituted or unsubstituted by a carboxy group.
- 18. The compound according to claim 16 wherein R.sup.2 is hydrogen, methyl, 1-carboxy-1-methylethyl, cyclopentyl, or ethyl.
- 19. The compound according to claim 9 wherein R.sup.4 and R.sup.5 is each selected from hydrogen, methyl, ethyl, carboxymethyl, methoxyethyl, cyanomethyl, propargyl, 4-carboxy-butan-1-yl, 2-amino-2-(methoxycarbonyl)ethyl, cyclopropylmethyl, propyl, cyclopentyl, prop-2-en-1-yl, butyl, hexyl, isopropyl, 2-hydroxyethyl, pyridyl, isoxazolylmethyl, thiazolylmethyl, chloropyridinyl, pyrazinyl, imidazolinyl, benzopyrazidinyl, acetyl, benzoyl, 3,4-dihydroxybenzoyl, 4-nitrobenzoyl, 4-methoxybenzoyl, 4-carboxybenzoyl, 4-aminobenzoyl, 2-furanoyl, 3,4-dihydroxycinnamoyl, carbamoyl, N-methylcarbamoyl and t-butyoxycarbonyl; or the groups R.sup.4 and R.sup.5 together with the nitrogen to which they are attached form a piperazinyl, triazolyl, pyrrolidinyl or piperidinyl group, each of which may be substituted or unsubstituted; or R.sup.4 and R.sup.5 together form an isopropylidene group.
- 20. A pharmaceutical composition comprising a compound of formula (Ia) as defined in claim 15 or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, in combination with a pharmaceutically acceptable excipient or diluent.
- 21. The pharmaceutical composition according to claim 20 in which the compound is 6R,7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido!-3- 1-(methylamino)-pyridinium-4-thiomethyl!ceph-3-em-4-carboxylic acid or pharmacuetically acceptable salts thereof.
- 22. A method of treating bacterial infections in humans and animals which method comprises administering a therapeutically effective amount of a compound of formula (Ia) as defined in claim 9 or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof to a patient in need thereof.
- 23. A compound and pharmaceutically acceptable salts and in-vivo hydrolysable esters thereof, selected from the group consisting of:
- 6R, 7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)- (R,S)-carboxy(3,4-dihydroxyphenyl)methyloxyimino!acetamido!-3- 1-(methylamino(pyridinium-4-thiomethyl!ceph-3-em-4-carboxylate;
- 6R, 7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)- (R)-carboxy(3,4-dihydroxyphenyl)methyloxyimino!acetamido!-3- 1-(methylamino(pyridinium-4-thiomethyl!ceph-3-em-4-carboxylate;
- 6R, 7R!-3- 1-Aminopyridinium-4-thiomethyl!-7- 2 (2-amino-4-thiazolyl)-2-(Z)- (R, S)-carboxy(3,4-dihydroxyphenyl)methyloxyimino!acetamido!ceph-3-em-4-carboxylate;
- 6R,7R!-3- 1-Aminopyridinium-4-thiomethyl!-7- 2-(2-amino-4-thiazolyl)-2-(Z)- (S)-carboxy (3,4-dihydroxyphenyl)methyloxyimino!acetamido!ceph-3-em-4-carboxylate;
- 6R, 7R!-3- 1-Aminopyridinium-4-thiomethyl!-7- 2-(2-amino-4-thiazolyl)-2-(Z)- (R)-carboxy(3,4-dihydroxyphenyl)methyloxyimino!acetamido!ceph-3-em-4-carboxylate;
- 6R, 7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)- 3,4-(methylenedioxy)benzyloxyimino!acetamido!-3- 1-(methylamino(pyridinium-4-thiomethyl)ceph-3-em-4-carboxylate;
- 6R, 7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido!-3- 1-(dimethylamino(pyridinium-4-thiomethyl!-ceph-3-em-4-carboxylate;
- 6R, 7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)-(1-carboxy-1-methylethoxyimino)acetamido!-3- 1-(methylamino(pyridinium-4-thiomethyl!ceph-3-em-4-carboxylate;
- 6R, 7R!-3-(1-Aminopyridinium-4-thiomethyl)-7- 2-(2-amino-4-thiazolyl)-2-(,Z)-(methoxyimino)acetamido!ceph-3-em-4-carboxylate;
- 6R,7R!- 2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido!-3- 1-(carboxymethylamino)pyridinium-4-thiomethyl!ceph-3-em-4-carboxylate;
- 6R, 7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido!-3- 1-(ethylamino(pyridinium-4-thiomethyl!ceph-3-em-4-carboxylate;
- 6R, 7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)-(cyclopentyloxyimino)acetamido!-3- 1-(methylamino(pyridinium-4-thiomethyl!ceph-3-em-4-carboxylate;
- 6R, 7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)-(hydroxyimino)acetamido!-3- 1-(methylamino(pyridinium-4-thiomethyl!ceph-3-em-4-carboxylate;
- 6R, 7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido!-3- 1-(4-carboxybutan-1-yl)aminopyridinium-4-thiomethyl!ceph-3-em-4-carboxylate;
- 6R, 7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)-(ethoxyimino) acetamido!-3- 1-(methylamino(pyridinium-4-thiomethyl!ceph-3-era-4-carboxylate;
- 6R,7R!-3- 1- (2S)-2-Amino-2-(methoxycarbonyl)ethylamino!pyridinium-4-thiomethyl!-7- 2-(2-amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido!ceph-3-em-4-carboxylate;
- 6R,7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino) acetamido!-3- 1-(cyclopropylmethylamino)pyridinium-4-thiomethyl!ceph-3-em-4-carboxylate;
- 6R, 7R!-3-(1-Aminopyridinium-4-thiomethyl)-7- 2-amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido!ceph-3-em-4-carboxylate;
- 6R, 7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino) acetamido!-3- 1-(propylamino(pyridinium-4-thiomethyl!-ceph-3-em-4-carboxylate;
- 6R, 7R!-7- 2-(2-Amino-4-thiazo 1 yl)-2-(Z)-(methoxyimino)acetamido!-3- 1-(cyclopentylamino(pyridinium-4-thiomethyl!ceph-3-em-4-carboxylate;
- 6R, 7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido!-3- 1-(prop-2-en-1-yl)aminopyridinium-4-thiomethyl!ceph-3-em-4-carboxylate;
- 6R, 7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido!-3- 1-butylaminopyridinium-4-thiomethyl!ceph-3-em-4-carboxylate;
- 6R,7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)(methoxyimino) acetamido!-3- 1-(hexylamino)pyridinium-4-thiomethyl!ceph-3-em-4-carboxylate;
- 6R,7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino) acetamido!-3- 1-(1-isopropyl)aminopyridinium-4-thiomethyl!ceph-3-em-4-carboxylate;
- 6R, 7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido!-2- 1- (2-hydroxyethyl)amino!pyridinium-4-thiomethyl!ceph-3-em-4-carboxylate;
- 6R, 7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido!-3- 1-(3,5-dimethylisoxazol-4-yl)methylaminopyridinium-4-thiomethyl!ceph-3-em-4-carboxylate;
- 6R, 7R!-7- 2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(Z)-(methoxyimino)acetamido!-3- 1-(methylamino)pyridinium-4-thiomethyl!ceph-3-em-4-carboxylate;
- 6R,7R!-3-(1-Amino-3-methoxy-2-methylpyridinium-4-thiomethyl)-7- 2-(2-amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido!-ceph-3-em-4-carboxylate;
- 6R, 7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido!-3- 1- (2-methoxyethyl)amino!pyridinium-4-thiomethyl!ceph-3-em-4-carboxylate;
- 6R, 7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido!-3- 1- (2-methyl-4-thiazolyl)m ethylamino!pyridinium-4-thiomethyl!ceph-3-em-4-carboxylate;
- 6R, 7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido!-3- 1- (cyanomethyl)amino!pyridinium-4-thiomethyl!ceph-3-em-4-carboxylate;
- 6R, 7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido!-3- 1-(prop-2-yn-1-ylamino)pyridinium-4-thiomethyl!ceph-3-em-4-carboxylate;
- 6R, 7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)-(methoximino) acetamido!-3- 1-(methylamino(pyridinium-4-thiomethyl!ceph-3-em-4-carboxylate-1-oxide; and
- 6R, 7R!-3-(1-Amino-2,6-dimethylpyridinium-4-thiomethyl)-7- 2-(2-amino-4-thiazolyl)-2-(Z)-(methoxyimino) acetamido!ceph-3-em-4-carboxylate.
- 24. The compound 6R,7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)- (R)-carboxy(3,4-dihydroxyphenyl)methyloxyimino!acetamido!-3- 1-(methylamino)pyridinium-4-thiomethyl!ceph-3-em-4-carboxylate or pharmaceutically acceptable salts thereof.
- 25. The pharmaceutical composition according to claim 12 in which the compound is 6R,7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)- (R)-carboxy(3,4-dihydroxyphenyl)methyloxyimino!acetamido!-3- 1-(methylamino)pyridinium-4-thiomethyl!ceph-3-em-4-carboxylate or pharmaceutically acceptable salts thereof.
- 26. The compound 6R,7R!-7- 2-(2-Amino-4-thiazolyl)-2-(Z)-(methoxyimino)acetamido!-3- 1-(methylamino)pyridinium-4-thiomethyl!ceph-3-em-4-carboxylic acid or pharmaceutically acceptable salts thereof.
- 27. The compound according to claim 3 wherein the phenyl group is 3,4-dihydroxyphenyl, 3,4-diacetoxy or methylenedioxyphenyl.
Priority Claims (4)
Number |
Date |
Country |
Kind |
8919945 |
Sep 1989 |
GBX |
|
8919946 |
Sep 1989 |
GBX |
|
9010265 |
May 1990 |
GBX |
|
9010299 |
May 1990 |
GBX |
|
Parent Case Info
This application is a continuation of Ser. No. 08/221,656 filed Apr. 1, 1994, abandoned, which is a continuation of Ser. No. 07/578,661 filed Sep. 4, 1990, abandoned.
US Referenced Citations (7)
Foreign Referenced Citations (2)
Number |
Date |
Country |
01537099 |
Sep 1985 |
EPX |
024865 |
Jun 1987 |
EPX |
Non-Patent Literature Citations (3)
Entry |
Journal of Heterocyclic Chemistry, vol. 11, No. 4, Aug. 1974, Action of Amines and Carbonyl Reagents on 3,5-Diphenyl-4-pyrone and its Thio . . . pp. 487-490. |
Bulletin of the chemical Society of Japan, vol. 51, 1978, Reactions of 4H-Pyran-4-thiones with Ammonia, Hydrazine and Guanidine, pp. 179-181. |
Journal of the Chemical Society, 1977, Preparation of NN'-Linked Bi(heteroaryls) from Dehydroacetic Acid and 2, 6-Dimethyl-4-pyrone, pp. 1428-1436. |
Continuations (2)
|
Number |
Date |
Country |
Parent |
221656 |
Apr 1994 |
|
Parent |
578661 |
Sep 1990 |
|